Table 1 Baseline information of prospective and validation cohort
| Â | Prospective cohort | ||
|---|---|---|---|
Characteristic | ATB group (n = 43) | LTBI group (n = 49) | P value |
Age (average) | Â | Â | Â |
| Â | 44.0 | 49.7 | 0.057 |
Gender | Â | Â | Â |
 Male (%) | 30 (69.8%) | 21 (42.9%) | 0.012 |
 Female (%) | 13 (30.2%) | 28 (57.1%) | |
T-SPOT.TB | Â | Â | Â |
 Panel A, spot count | 88 | 31 | 0.002 |
 Panel B, spot count | 141 | 41 | 0.009 |
Contact with ATB | Â | Â | Â |
 Yes (%) | 2 (4.7%) | 49 (100%) | / |
 No (%) | 41 (95.3%) | 0 (0%) | |
BCG vaccination history | Â | Â | Â |
 Yes (%) | 6 (14.0%) | 31 (63.3%) | 0.000 |
 No/cannot remember (%) | 37 (86.0%) | 18 (36.7%) | |
Clinical manifestations | Â | Â | Â |
 Coughing with expectoration (%) | 36 (83.7%) | 17 (34.7%) | 0.000 |
 Chest tightness or pain (%) | 4 (9.3%) | 0 (0%) | 0.044 |
 Hemoptysis (%) | 3 (7.0%) | 0 (0%) | 0.098 |
 Night sweats (%) | 1 (2.3%) | 1 (2.0%) | 1.000 |
 Fever (%) | 1 (2.3%) | 1 (2.0%) | 1.000 |
 Inappetence (%) | 0 (%) | 0 (0%) | / |
 Lung cavity (%) | 17 (39.5%) | / | / |
Comorbidity | Â | Â | Â |
 Diabetes mellitus (%) | 5 (11.6%) | 1 (2.0%) | 0.094 |
 CHB (%) | 6 (16.3%) | 2 (4.1%) | 0.140 |
 HIV (%) | 0 (0%) | 0 (0%) | / |
 Hypertension (%) | 1 (2.3%) | 5 (10.2%) | 0.209 |
 Silicosis (%) | 1 (2.3%) | 0 (0%) | 0.467 |
| Â | Validation cohort | Â | Â |
|---|---|---|---|
Characteristic | LTBI (n = 104) | ATB (n = 209) | P value |
Gender | Â | Â | Â |
 Male (%) | 43 | 134 | 0.0001 |
 Female (%) | 56 | 66 |  |
Age | 45.17 ± 1.527 | 47.80 ± 1.449 | 0.2621 |
Nationality | Â | Â | Â |
 Han | 104 | 209 | – |
District | Â | Â | Â |
 Chongqing | 61 | 54 |  < 0.0001 |
 Around Shanghai | 43 | 155 |  |